

Hypocrites! The American Medical Association Is Very Quietly Trying To Change Their Position On Hydroxychloroquine To Treat COVID-19

ADMIN 3 DAYS AGO



Resolution: 509 (November 2020)
Page 3 of 6

1 Whereas, The COVID-19 pandemic is a serious medical issue, people are dying, and
2 physicians must be able to perform as sagacious prescribers; therefore be it
3
4 RESOLVED, That our American Medical Association rescind its statement calling for physicians
5 to stop prescribing hydroxychloroquine and chloroquine until sufficient evidence becomes
6 available to conclusively illustrate that the harm associated with use outweighs benefit early in
7 the disease course. Implying that such treatment is inappropriate contradicts AMA Policy
8 H-120.988, "Patient Access to Treatments Prescribed by Their Physicians," that addresses off
9 label prescriptions as appropriate in the judgement of the prescribing physician (Directive to
10 Take Action); and be it further
11
12 RESOLVED, That our AMA rescind its joint statement with the American Pharmacists
13 Association and American Society of Health System Pharmacists, and update it with a joint
14 statement notifying patients that further studies are ongoing to clarify any potential benefit of
15 hydroxychloroquine and combination therapies for the treatment of COVID-19 (Directive to Take
16 Action); and be it further
17
18 RESOLVED, That our AMA reassure the patients whose physicians are prescribing
19 hydroxychloroquine and combination therapies for their early-stage COVID-19 diagnosis by
20 issuing an updated statement clarifying our support for a physician's ability to prescribe an FDA-
21 approved medication for off label use, if it is in her/his best clinical judgement, with specific
22 reference to the use of hydroxychloroquine and combination therapies for the treatment of the
23 earliest stage of COVID-19 (Directive to Take Action); and be it further
24
25 RESOLVED, That our AMA take the actions necessary to require local pharmacies to fill valid
26 prescriptions that are issued by physicians and consistent with AMA principles articulated in
27 AMA Policy H-120.988, "Patient Access to Treatments Prescribed by Their Physicians,"
28 including working with the American Pharmacists Association and American Society of Health
29 System Pharmacists. (Directive to Take Action)

Fiscal Note: Modest - between \$1,000 - \$5,000

Received: 10/23/20

The American Medical Association is very quietly trying to change its position over the use of hydroxychloroquine to treat coronavirus patients.

In March the American Medical Association came out against the use of hydroxychloroquine after President Trump touted its use to treat the Wuhan virus. The media, Dr. Fauci, and liberal medical journals went nuts and did everything to dissuade Americans from seeking treatment.

"We caution hospitals, health systems, other entities, and individual practitioners that no medication has been FDA-approved for use in COVID-19 patients," the AMA's March statement reads in regards to HCQ and similar unconventional treatments. "Definitive evidence for the role of these drugs in treating COVID-19 patients has not been determined through robust clinical trials; decisions to use these medications off-label must be made with extreme caution and careful monitoring. Physicians, pharmacists, patients and policymakers must understand that these medications have dangerous side effects that may lead to patient harm, including fatal cardiac arrhythmias."

This month the AMA discussed considering a resolution to reverse their stance on HCQ because the potential for good may supersede the threat of any potentially harmful side effects.

RESOLVED, THAT OUR AMERICAN MEDICAL ASSOCIATION RESCIND ITS STATEMENT CALLING FOR PHYSICIANS TO STOP PRESCRIBING HYDROXYCHLOROQUINE AND CHLOROQUINE UNTIL SUFFICIENT EVIDENCE BECOMES AVAILABLE TO CONCLUSIVELY ILLUSTRATE THAT THE HARM ASSOCIATED WITH USE OUTWEIGHS BENEFIT EARLY IN THE DISEASE COURSE," THE MEMO READS.

A memo showed that the AMA was considering a joint statement with the American Pharmacists Association and the American Society of Health-System Pharmacists that further studies are ongoing to "clarify any potential benefit of hydroxychloroquine and combination therapies for the treatment of COVID-19."

Resolution: 509 (November 2020)

Page 3 of 6

1 Whereas, The COVID-19 pandemic is a serious medical issue, people are dying, and
2 physicians must be able to perform as sagacious prescribers; therefore be it

3

4 **RESOLVED, That our American Medical Association rescind its statement calling for physicians**
5 **to stop prescribing hydroxychloroquine and chloroquine until sufficient evidence becomes**
6 **available to conclusively illustrate that the harm associated with use outweighs benefit early in**
7 **the disease course. Implying that such treatment is inappropriate contradicts AMA Policy**
8 **H-120.988, "Patient Access to Treatments Prescribed by Their Physicians," that addresses off**
9 **label prescriptions as appropriate in the judgement of the prescribing physician (Directive to**
10 **Take Action); and be it further**

11

12 **RESOLVED, That our AMA rescind its joint statement with the American Pharmacists**
13 **Association and American Society of Health System Pharmacists, and update it with a joint**
14 **statement notifying patients that further studies are ongoing to clarify any potential benefit of**
15 **hydroxychloroquine and combination therapies for the treatment of COVID-19 (Directive to Take**
16 **Action); and be it further**

17

18 **RESOLVED, That our AMA reassure the patients whose physicians are prescribing**
19 **hydroxychloroquine and combination therapies for their early-stage COVID-19 diagnosis by**
20 **issuing an updated statement clarifying our support for a physician's ability to prescribe an FDA-**
21 **approved medication for off label use, if it is in her/his best clinical judgement, with specific**
22 **reference to the use of hydroxychloroquine and combination therapies for the treatment of the**
23 **earliest stage of COVID-19 (Directive to Take Action); and be it further**

24

25 **RESOLVED, That our AMA take the actions necessary to require local pharmacies to fill valid**
26 **prescriptions that are issued by physicians and consistent with AMA principles articulated in**
27 **AMA Policy H-120.988, "Patient Access to Treatments Prescribed by Their Physicians,"**
28 **including working with the American Pharmacists Association and American Society of Health**
29 **System Pharmacists. (Directive to Take Action)**

Fiscal Note: Modest - between \$1,000 - \$5,000

Received: 10/23/20

What ended up happening was that the AMA did not rescind their objection to physicians prescribing HCQ but reaffirmed its policy to encourage Doctors to use their own judgment to prescribe drugs off label to treat COVID.

The AMA has blood on their hands, for the sake of politics they came out against HCQ, and now they are using double talk to save face.

[Publishedreporter.com](https://www.publishedreporter.com)

Written by Staff Writer – December 16, 2020